The conversation about antiangiogenic treatment for breast cancer continues. Published in the 12/1/11 issue of the Journal of Clinical Oncology, Drs. Schneider and Sledge elucidate the topic in the wake of the US Food and Drug Administration’s (FDA) revocation of Avastin® (bevacizumab) as an approved treatment for metastatic breast cancer. You may recall that Dr. Sledge is the Immediate Past President of the American Society of Clinical Oncology (ASCO); both Sledge and Schneider are oncologists at the Indiana University Melvin and Bren Simon Cancer Center.
5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.